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The role ofchelating agents for the preven-
tion, intervention, and treatment of expo-
sures to toxic metals was the topic ofa con-
ference held at the National Institute of
Environmental Health Sciences, 22-23
September 1994. The objective of the con-
ference was to review experimental and
clinical studies concerned with the effective-
ness and potential toxicity of chelating
agents used to reduce the body burden of
various metals and to identify research
needs in the area of chelation. The confer-
ence was prompted by emerging evidence
that low-level exposures to metals may
result in toxic effects not previously recog-
nized. For example, the recent interest in
use of chelation as an intervention strategy
to reduce blood lead levels followed the
awareness that exposure to lead in infants
and young children resulting in blood lead
levels as low as 10-15 )ig/dl may impair
cognitive and behavioral development (1).
The question increasingly asked is to what
degree, ifany, does increased excretion ofa
toxic metal reverse established toxicity? For
example, does reduction in blood lead levels
reverse the impairment of cognitive and
behavioral development in children? Does
the process of chelation cause potentially
dangerous redistribution oflead to suscepti-
ble organs from those less susceptible to
lead toxicity? While intervention for toxici-
ty from any metal includes removal from
exposure, what are the indications for using
chelating agents that enhance excretion of
metals?
Complete answers to these questions
may not be currently available, but discus-
sion of benefits and problems related to
chelation therapy should help identify areas
needing further study. The conference par-
ticipants were asked to share current data
and to identify gaps in data necessary to
obtain a better understanding ofthe proper
place of chelating agents in the manage-
ment ofmetals exposure and toxicity.
Chelation ofLeadwith EDTA
It was suggested at the conference that the
essential characteristics of an ideal lead
chelator are 1) the ability to reduce the cel-
lular lead burden in the target cells for lead
toxicity, 2) the ability to restore or prevent
lead-induced loss of cell function, 3) the
absence of adverse effects produced by
interfering with homeostasis and utiliza-
tion of essential trace elements, and 4) no
or little intrinsic toxicity (2).
Historically, the drug of choice in
treatment oflead toxicity is EDTA (disodi-
um ethylenetetraacetate) (1,3). The com-
mon practice oftreating children with high
lead exposure (blood lead levels of70-100
pg/dl) with a combination of EDTA and
BAL (British anti-Lewisite, Dimercaprol) is
believed to reduce mortality from lead
encephalopathy from about 30% to 1 or
2% and is more effective under these cir-
cumstances than treatment with EDTA
alone. EDTA may not be appropriate for
treating low-level lead exposures because it
must be given parenterally, and it can be
toxic in that it increases excretion of some
essential metals. EDTA produces substan-
tial diuresis of zinc and a temporary
30-40% decrease in plasma zinc (4).
The relationship between blood lead
concentration and the quantity of lead
excreted with EDTA treatment is nonlin-
ear. Arithmetic increases in blood lead are
associated with exponential increases in
excretion of lead. As blood lead levels
decrease, the risk-benefit ratio for EDTA
becomes progressively less favorable. The
lead-chelate complex is filtered by the renal
glomerulus with a biological half-time of
1.5 hr. In subjects with normal renal func-
tion most of the lead-chelate complex is
excreted within 8 hr, but excretion may
take as long as 3 days in persons with renal
failure. In children in which exposure to
lead is ofrelatively short duration, the cor-
relation between blood lead and chelatable
lead is variable. In adults with remote past
exposure, the correlation between blood
lead and chelatable lead is poor. A larger
fraction of the lead burden in children
resides in soft tissues compared to adults.
After a single challenge dose of EDTA,
lead is excreted largely from blood and soft
tissues (5-7). However, a single EDTA
treatment does not produce a dramatic
decrease in bone lead as measured by L X-
ray fluorescence (L-XRF) in children (8,9).
K-XRF measurements of bone lead are
superior to chelation challenge tests as a
marker of long-term lead exposure (5). In
adults, bone lead measured by trans-iliac
biopsies or by in vivo tibial K-XRF corre-
lates well with chelatable lead during long-
term chelation therapy. The upper limit of
normal lead-chelate excretion is about 650
pg/day for adults and is comparable to that
reported in children when normalized for
body mass. In adults with elevated bone
lead from chronic lead poisoning, there is
decrease in blood, bone, and chelatable lead
during long-term chelation. Reequilibration
between blood and bone lead takes about 2
weeks (7>10).
EDTA nephrotoxicity as described in
earlier literature is not found with the cur-
rently available pyrogen-free calcium salt at
recommended dosage (<50 mg/kg) (11).
Experimental studies of efficacy of EDTA
and dimercaptosuccinic acid (DMSA) sug-
gest that the toxicokinetics oflead differ in
older animals, and there is less reduction in
liver and kidney lead than in younger rats.
Excretion of essential trace metals after
chelation therapy with EDTA or DMSA is
greater in older animals than in younger
animals (12).
Chelation ofLeadwith DMSA
The Food and Drug Administration has
recently licensed the drug DMSA (suc-
cimer) for reduction of blood lead levels
.45 pg/dI. This decision was based on the
demonstrated ability of DMSA to reduce
blood lead levels. An advantage ofthis drug
is that it can be given orally. However,
there is no information regarding its effec-
tiveness in reversing the clinical effects of
low-level lead exposure, including effects on
the central nervous system. Interest in using
DMSA to treat low-level lead exposure has
prompted studies regarding the source of
the endogenous lead removed by this drug,
its possible redistribution between organs,
and whether DMSA increases gastrointesti-
nal absorption of lead, since it is adminis-
tered orally. Answers to these questions are
incomplete. While studies in animals show
that DMSA does not seem to redistribute
lead into the brain from other organs, there
is no consensus as to the effectiveness of
DMSA in removal of lead from brain
and/or bone (13). One study using stable
isotopes of lead suggests that DMSA may
enhance gastrointestinal absorption oflead,
Address correspondence to R.A. Goyer, NIEHS,
PO Box 12233, Research Triangle Park, NC 27709
USA.
Volume 103, Number 11, November 1995 * EnvironmentalHealth Perspectives 1048Meeting Report - Chelating agents
but this may be related to dose, duration of
treatment and, of course, the amount of
lead in the gut (14).
Results ofa clinical trial were presented
in which the effectiveness of DMSA in
removal of lead from 19 children with
blood lead levels of 50-69 pg/dl was com-
pared to treatment of 4 comparable chil-
dren with EDTA. DMSA decreased blood
lead by 61%, whereas in 4 children treated
with EDTA, blood lead decreased by 45%.
The group of 4 children receiving EDTA
was too small to evaluate for statistical sig-
nificance. However, urinary lead was com-
parable in the two groups. There is a posi-
tive correlation between blood lead levels
and half-time elimination of DMSA, sug-
gesting that lead may interfere with renal
excretion of DMSA and possibly other
drugs. Concomitant antibiotics might
slightlydecrease the efficacy ofDMSA (15).
Most of the DMSA excreted in the
urine ofhumans is in the form ofa mixed
disulfide in which each ofthe sulfur atoms
ofDMSA is in disulfide linkage with a cys-
teine molecule. There is a small amount of
excreted DMSA in which only one mole-
cule of cysteine is in disulfide linkage with
DMSA. In an experimental study it was
found that synthetic DMSA:cysteine (1:2)
mixed disulfide mobilizes and increases the
excretion oflead in rats preloaded with lead
acetate (16).
The actions of DMSA and EDTA on
cellular metabolism oflead have been com-
pared in cultures ofosteoclastic bone cells.
Both DMSA and EDTA have distinct and
complex effects on the cellular metabolism
oflead. Both compounds reduce the size of
the largest and most stable subcellular pool
oflead. However, EDTA increases the size
of the most rapidly exchanging Pb2+ pool
without effecting a significant reduction in
the total cellular burden. In contrast,
DMSA only slightly increases the interme-
diate lead pool, but effectively reduces the
total cellular lead burden. These experi-
ments indicate that DMSA alters the trans-
fer of lead within cells such that a greater
percentage of total cellular lead present in
cells is in a readily exchangeable pool.
Neither DMSA nor EDTA is particularly
effective in restoring lead-impaired cell
functions such as protein synthesis, por-
phyrin synthesis, heme synthesis, and
osteocalcin expression, even though cellular
levels oflead are diminished (2).
Experimental studies in animals have
shown that, because of differences in the
toxicokinetics of lead in animals at differ-
ent ages, older (mature) animals may
require larger doses ofchelating agent than
younger animals to remove a particular
amount of lead. Also, EDTA increases
excretion of essential metals, calcium, and
zinc, whereas DMSA increases the excre-
tion of copper. Human studies have also
shown that excretion of copper, and to a




Penicillamine has been used to chelate
toxic metals including copper (in Wilson's
disease) as well as lead, mercury, and
arsenic. It has been approved by the FDA
for treatment of Wilson's disease, cysti-
nosis, and rheumatoid arthritis but not for
lead poisoning, primarily to avoid its mis-
use in the workplace. Nevertheless, a sub-
stantial body of experimental and clinical
data exists regarding the pharmacology and
utility of penicillamine in both adult and
childhood lead poisoning. Experience at
the Lead Clinic of the Boston Children's
Hospital suggests that D-penicillamine
increases excretion of lead with a minimal
risk to children with blood lead levels <35
pg/dl. Penicillamine may produce substan-
tial reduction in blood lead levels and less
rebound than treatment with DMSA or
EDTA probably due to the continuity of
the penicillamine treatment. Potential side
effects include hypersensitivity reactions,
particularly in subjects allergic to penicillin
(19).
Effects ofLowering Blood Lead by
Chelation
NIEHS is sponsoring a randomized, multi-
center clinical trial ofabout 1300 children
under 24 months ofage is currently testing
the effectiveness of succimer in reversing
the slower cognitive and behavioral devel-
opment in children with blood lead levels
between 20 and 44 pg/dl. The trial will be
conducted on a double-blind basis, and fol-
low-up of the children will extend for at
least 2 years. Other interventions such as
home cleanup and nutritional supplemen-
tation will be done for all children. Results
will not be available for some time (20).
A preliminary study presented at the
conference showed that lowering blood lead
levels in children does not result in a signifi-
cant beneficial effect on growth (length or
height). However, the study did not involve
a control group and did not assess dietary
and socioeconomic factors (21).
Chelation ofMercury
Another objective ofthe conference was to
review the effectiveness of drugs for
removal of mercury. The two chelating
agents that have been most studied for
removal ofmercury are DMSA and a relat-
ed drug, 2,3-dimercapto-1-propanesulfonic
acid, (DMPS, dimaval) (22). DMSA and
DMPS are chemical analogs of BAL
(dimercaprol) and can be administered
orally. However, the two drugs are bio-
transformed differently in humans. More
than 90% of DMSA excreted in urine of
humans is in the form ofa mixed disulfide
in which each of the sulfur atoms of
DMSA is in disulfide linkage with a cys-
teine molecule. After DMPS administra-
tion, however, acyclic and cyclic disulfides
ofDMPS are the major metabolites in the
urine (23,24). Both DMSA and DMPS
increase the urinary excretion ofmercury.
Animal studies have shown that DMPS
exhibits some organ specificity in the chela-
tion ofmercury (25,26). In rats exposed to
mercuric chloride or mercury vapor,
administration of DMPS increased urinary
excretion of mercury and decreased renal
mercury content. The increase in urinary
excretion was directly proportional to the
renal burden of mercury in rats injected
with mercuric chloride or exposed to mer-
cury vapor. Thus, DMPS may be ofpoten-
tial use to measure the renal burden oflead
and mercury.
About two-thirds of the mercury
excreted in persons with mercury-contain-
ing dental amalgams appears to be derived
from mercury vapor released earlier from
their amalgams, and a highly significant
positive correlation has been found
between numbers and sizes ofamalgam fill-
ings and urinary mercury excretion follow-
ing DMPS administration (27).
In a clinically controlled trial in which
half the subjects received DMSA and the
other half received a placebo, DMSA
increased the urinary excretion of lead,
copper, mercury, and, to a lesser degree,
zinc in the first 24 hr; lead excretion
increased about 10-fold over controls,
whereas both copper and mercury doubled.
Although DMSA enhances excretion of
mercury, lead is the toxic metal most clear-
ly affected by DMSA treatment (17).
While elemental or inorganic mercury
can be removed from tissues by chelating
agents, it is unlikely that methylmercury can
be chelated (28). The methylmercury
cation, CH3Hg+, forms a thermodynamical-
ly stable bond with the deprotonated thiol
group. Thus, the formation of only one
bond between mercury atom and another
ligand predudes the formation ofring struc-
tures needed to produce a metal chelate.
However, the strong linear bond formed
between mercury and a thiol group allows
the formation of a variety of complexes,
whereby thiol-containing compounds may
be used for antidotal therapy. Exchange
with the protein-bound mercurial should be
rapid (29), provided that the thiol com-
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pound to be used as an antidote can pene-
trate the macrostructure ofproteins to reach
the site ofthe bound mercury.
Metallothionein, aNatural Chelator
Metallothionein (MT) was discovered in
1957 as a cadmium-binding protein in the
renal cortex of the horse and is character-
ized as a low molecular weight (>9000 Da),
cysteine-rich, metal-binding protein.
Mammalian MT contains 61 amino acids.
The protein contains no aromatic amino
acids or histidine. Twenty ofthe 61 amino
acids are cysteine, and are arranged in a
highly conserved sequence which is
observed in vertebrate, invertebrate, yeast,
and plant MT. Metals bind to MT in
metal-thiolate complexes exhibiting tetra-
hedral (cadmium, zinc) or trigonal (cop-
per) geometry. Two major isoforms ofMT
(designated MT I and II) have been identi-
fied in most species and are controlled sep-
arately by different genes. Humans contain
subforms of the two isoforms. Recently, a
third isoform (growth inhibitory factor,
MT III) has been identified in the brain.
The MT molecule is divided into two dis-
tinct metal-binding domains. The carboxyl
terminal halfof the molecule is designated
the a-domain and represents amino acids
30-61. It contains 11 cysteinyl residues
and binds four atoms of zinc or cadmium
or six atoms of copper. The {-domain is
the amino-terminal half of MT and con-
tains nine cystinyl residues. This domain
binds three ions ofzinc or cadmium or six
copper ions. MT exhibits numerous bio-
logical and physiological functions. It
appears to have a role in zinc and copper
metabolism. The induction ofMT protects
organisms from toxic metals such as cadmi-
um. MT also exhibits free-radical scavaging
activity. Medically, the induction ofintesti-
nal MT by zinc therapy is correlated with
normal to negative copper balance in
patients with Wilson's disease. Renal MT
induction also protects the intestine against
the toxic effects of cisplatin treatment.
However, tumor cells that are resistant to
electrophilic antineoplastic agents exhibit
increased cellular MT levels. Thus, MT
may protect some tumor cell types against
the effects ofcertain antitumor drugs (30).
The toxicity of the cadmium-metal-
lothionein complex precludes any consider-
ation ofuse ofthis natural metal-ligand for
clinical use to enhance excretion ofmetals.
Chelation ofCadmium
Developing an effective chelation therapy
for cadmium is difficult because cadmium is
tightly bound to metallothionein in liver
and kidney. Cadmium in liver has a long
half-life (about 30 years in humans) and is
gradually mobilized from liver to kidney,
which is considered the critical organ for
cadmium toxicity. The cadmium-metal-
lothionein complex is extremely toxic to the
kidney (31), and most chelating agents that
do remove cadmium from the liver are
excreted by the kidney, producing nephro-
toxicity. Therefore, the best approach to
chelating cadmium from the liver is through
bile, before it reaches the kidney. A number
of substituted dithiocarbamate compounds
with a pair of sulfur atoms that serve as
donors to cadmium are the most promising
types ofchelating agents for cadmium mobi-
lization. Sodium N-(4-methoxybenzyl)-D-
glucamine dithiocarbamate (MeOBGDTC)
is one of the most effective for removing
cadmium from liver and kidney. Cadmium
is then excreted in bile complexed with
MeOBGDTC and glutathione (32,33).
Although MeOBGDTC and other similar
compounds have been shown to be effective
in removing cadmium from tissues ofexper-
imental animals with cadmium exposure,
efficacy in humans has not been demon-
strated.
Selective Removal ofCopper Bound
to Metallothionein by
Tetrathiomolybdate
The affinity ofcopper for binding to MT is
higher than that of zinc or cadmium.
However, it has been recently shown that
copper can be removed both in vitro and in
vivo by tetrathiomolybdate (TTM) without
affecting the other two metals bound to
MT. The mechanisms whereby TTM
removes copper have been studied in a rat
model for Wilson's disease, the LEC rat,
which expresses a genetically defective cop-
per-dependent ATPase that regulates cop-
per efflux (34).
TTM appears to remove copper from
MT and facilitates excretion by three dif-
ferent reaction pathways. When the
amount ofTTM (from repeated injections)
is less than half the amount of copper
bound to MT, TTM appears .to remove
copper only from cytosolic MT; Zn-MT
and apo-MT remain in the cytosol
(Cu,Zn-MT -* Cu,Zn-MT/TTM -> Zn-
MT/apo-MT). Copper remaining in the
liver is present as a copper-molybdenate-
sulfur polymer. A putative dimer,
MT-TTM connected by a (TTM)-S-Cu-
S-(MT) bridge, is also formed. When
TTM is greater than half the amount of
copper, the TTM dissociates copper from
the MT-TTM complex and copper for-
merly bound to MT becomes associated
with a high molecular weight protein in the
cytosol. The copper-molybdenate complex
bound to the high molecular weight pro-
tein is assumed to be a soluble oligomer
complex and is thought to be excreted
from the liver. A third pathway for removal
ofcopper from MT by TTM is by facilitat-
ing the polymerization of the soluble (Cu-
S-MoS2-S-) polymer to an insoluble (-Cu-
S-MoS2-S) polymer (35).
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Design ofNew Chelating Agents for
Removal ofCadmium, Copper, and
Actinides
For the design and development of new
chelating agents for reducing body burden
of metals such as cadmium, copper, and
the radioactive actinide elements, Pu(IV),
Np(V), and U(VI), specific chemical, phys-
iological, and pharmacological properties
must be included in the molecule (36,34.
There are various approaches to achieving
the appropriate design. One approach is to
identify an indicator compound by selec-
tive screening of possible candidates.
Another approach is to start by identifying
the possible ways in which a chelating
agent structure can be designed to match
the geometric and chemical preferences of
the central (toxic) metal ion under consid-
eration. This method is illustrated by the
development of chelating agents to mobi-
lize cadmium from its intracellular deposit
(38). Compounds in this category include
dithiocarbamates, mono- and diesters of
meso-2,3-dimercaptosuccinic acid.
The design of an improved chelating
agent for lead has involved an examination
ofa series ofbidentate ligand functionalities
that show some significant affinities orpref-
erences for lead (36). This was followed by
the design and synthesis ofmultidentate lig-
ands based on the coordination properties
of Pb2+ found in simple natural systems,
particularly the low-molecular weight pep-
tides found in plants or other organisms
(39). Some of the lead-sequestering agents
identified by this approach are the thiohy-
droamato complexes, and mono- and bis-
(hydroxypyridinethione) ligands (40).
Conclusion
In summary, the conference achieved its
purpose of highlighting the current pat-
terns ofclinical usage ofchelating agents as
well as the current status of promising
experimental drugs. Insights were provided
as to how to design new agents.
The conference also brought into focus
questions about the effectiveness of cur-
rently available drugs. Although drugs in
current use are effective in lowering levels
of toxic metal in body fluids, there is little
information about removal of toxic metals
for tissues or reversal of toxic effects. The
issues discussed in the conference have pro-
vided the basis for identifying the following
research needs:
1) Determine the sites from which lead
is removed during chelation therapy and
identify which chelator is most effective in
removing lead from the nervous system.
2) Determine if intervention with
chelating agents enhances the reversal of
functional impairment of cognitive and
behavioral development associated with
exposure to lead.
3) Better characterize essential metal
excretion during intervention with chelat-
ing agents, particularly DMSA.
4) Determine whether orally adminis-
tered chelating agents enhance absorption
of toxic metals from the gastrointestinal
tract.
5) Determine whether there are advan-
tages to the simultaneous use of multiple
chelating agents.
6) Perform longer-term experiments on
lead-loaded primates to investigate removal
oflead from bone. Such information might
be useful in devising clinical treatments to
remove lead from bone. How do different
intervention regimens with or without
chelating agents compare in terms of
removal of lead from tissues particularly
the nervous system and bone? This infor-
mation might help avoid later problems
which arise under circumstances when such
lead is remobilized as a result ofpregnancy
or disorders of bone metabolism such as
osteoporosis.
7) Develop and clinically test chelating
agents for removal of cadmium. Further
test the use of DMSA and DMPS for
removal ofmercury.
8) Assess the use ofless common toxic
metals for effective antagonists. These
include thallium, beryllium, and the
radioactive actinide metals.
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The thirty-fifth ASCB Annual Meeting will include symposia, mini symposia, poster sessions, special interest
subgroup meetings, special lectures, workshops, and other events that reflect the eclectic nature of cell biol-
ogy and the tremendous impact of cell biology on all aspects of biomedical research. Each facet of the pro-
gram incorporates venues designed to increase interaction among scientists and the exchange of ideas
among all participants.
EXHIBITS
The commercial exhibits will be open 9:00AM-4:00PM Sunday-Tuesday, December 10-12 and Wednesday,
December 13 from 9:00AM-3:00PM. There will be approximately 450 exhibit booths, allowing registrants
the opportunity to examine state-of-the-art products and services. The ASCB will provide complimentary
refreshments each morning and afternoon in the exhibit hall.
For information contact:
TheAmerican Society for Cell Biology
9650 Rockville Pike, Bethesda, MD 20814-3992
FAX: (301) 530-7139 E-mail: ascbinfobascb.faseb.org
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